1 H. Sung, J. Ferlay, R.L. Siegel, et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA A Cancer J Clin, 71 (3) (2021), pp. 209-249

2 M.S.Z. SalemCancer: some genetic considerations Egypt J Med Hum Genet, 16 (1) (2015), pp. 1-10

3 C. Espina, K. Straif, S. Friis, et al.European Code against Cancer 4th Edition: environment, occupation and cancer Cancer Epidemiol, 39 (2015), pp. S84-S92

4 B. Ruiz-Núñez, L. Pruimboom, D.A.J. Dijck-Brouwer, et al.Lifestyle and nutritional imbalances associated with Western diseases: causes and consequences of chronic systemic low-grade inflammation in an evolutionary context J Nutr Biochem, 24 (7) (2013), pp. 1183-1201

5 M.S. DonaldsonNutrition and cancer: a review of the evidence for an anti-cancer diet Nutr J, 3 (2004), p. 19

6 Z. Wang, P. McLoone, D.S. MorrisonDiet, exercise, obesity, smoking and alcohol consumption in cancer survivors and the general population: a comparative study of 16 282 individuals Br J Cancer, 112 (3) (2015), pp. 572-575

7 D.T. Debela, S.G. Muzazu, K.D. Heraro, et al. New approaches and procedures for cancer treatment: current perspectives, SAGE Open Med (2021;9), Article 20503121211034366

8 H.E. Barker, J.T.E. Paget, A.A. Khan, et al.The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence Nat Rev Cancer, 15 (7) (2015), pp. 409-425

9 M. Arruebo, N. Vilaboa, B. Sáez-Gutierrez, et al.Assessment of the evolution of cancer treatment therapies Cancers, 3 (3) (2011), pp. 3279-3330

10 K. Nurgali, R.T. Jagoe, R. AbaloEditorial: adverse effects of cancer chemotherapy: anything new to improve tolerance and reduce sequelae? Front Pharmacol, 9 (2018), p. 245

11 M.T. Amjad, A. Chidharla, A. Kasi Cancer chemotherapy. In: StatPearls [Internet]. Treasure Island (FL), StatPearls Publishing (2022)

12 Q. Gao, G. Zhou, S.J. Lin, et al.How chemotherapy and radiotherapy damage the tissue: comparative biology lessons from feather and hair models Exp Dermatol, 28 (4) (2019), pp. 413-418

13 S. Tohme, R.L. Simmons, A. TsungSurgery for cancer: a trigger for metastases Cancer Res, 77 (7) (2017), pp. 1548-1552

14 R. Baskar, K.A. Lee, R. Yeo, et al.Cancer and radiation therapy: current advances and future directions Int J Med Sci, 9 (3) (2012), pp. 193-199

15 G.Y. Wan, Y. Liu, B.W. Chen, et al.Recent advances of sonodynamic therapy in cancer treatment Cancer Biol Med, 13 (3) (2016), pp. 325-338

16 P. Agostinis, K. Berg, K.A. Cengel, et al.Photodynamic therapy of cancer: an update CA A Cancer J Clin, 61 (4) (2011), pp. 250-281

17 C. Pucci, C. Martinelli, G. CiofaniInnovative approaches for cancer treatment: current perspectives and new challenges Ecancermedicalscience, 13 (2019), p. 961

18 S. Varghese, S.D. RabkinOncolytic Herpes simplex virus vectors for cancer virotherapy Cancer Gene Ther, 9 (12) (2002), pp. 967-978

19 A.M. Bradley, M. Devine, D. DeRemerBrentuximab vedotin: an anti-CD30 antibody-drug conjugate Am J Health Syst Pharm, 70 (7) (2013), pp. 589-597

20 G. Yeldag, A. Rice, A. Del Río HernándezChemoresistance and the self-maintaining tumor microenvironment Cancers, 10 (12) (2018), p. 471

21 L.T.H. Phi, I.N. Sari, Y.G. Yang, et al.Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment Stem Cell Int, 2018 (2018), Article 5416923

22 F.Y. Du, Q.F. Zhou, W.J. Sun, et al.Targeting cancer stem cells in drug discovery: current state and future perspectives World J Stem Cell, 11 (7) (2019), pp. 398-420

23 S. AkhondzadehThe importance of clinical trials in drug development Avicenna J Med Biotechnol (AJMB), 8 (4) (2016), p. 151

24 S. Sauer, D.R. Reed, M. Ihnat, et al.Innovative approaches in the battle against cancer recurrence: novel strategies to combat dormant disseminated tumor cells Front Oncol, 11 (2021), Article 659963

25 A. Mitra, L. Mishra, S. LiEMT, CTCs and CSCs in tumor relapse and drug-resistance Oncotarget, 6 (13) (2015), pp. 10697-10711

26 Z. Yu, T.G. Pestell, M.P. Lisanti, et al.Cancer stem cells Int J Biochem Cell Biol, 44 (12) (2012), pp. 2144-2151

27 A. Agliano, A. Calvo, C. BoxThe challenge of targeting cancer stem cells to halt metastasis Semin Cancer Biol, 44 (2017), pp. 25-42

28 D. Hanahan, R.A. WeinbergHallmarks of cancer: the next generation Cell, 144 (5) (2011), pp. 646-674

29 U. Sack, A. Tarnok, F. Preijers, et al.Editorial: modulation of human immune parameters by anticancer therapies Front Immunol, 11 (2020), Article 621556

30 E.Y.H.P. Lee, W.J. MullerOncogenes and tumor suppressor genes Cold Spring Harbor Perspect Biol, 2 (10) (2010), p. a003236

31 N. Rivlin, R. Brosh, M. Oren, et al.Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis Genes Cancer, 2 (4) (2011), pp. 466-474

32 S. SellCellular origin of cancer: dedifferentiation or stem cell maturation arrest? Environ Health Perspect, 101 (Suppl 5) (1993), pp. 15-26

33 A.Z. Ayob, T.S. RamasamyCancer stem cells as key drivers of tumour progression J Biomed Sci, 25 (2018), p. 20

34 L. Walcher, A.K. Kistenmacher, H. Suo, et al.Cancer stem cells-origins and biomarkers: perspectives for targeted personalized therapies Front Immunol, 11 (2020), p. 1280

35 Y.S. Kim, A.M. Kaidina, J.-H. Chiang, et al.Cancer stem cell molecular markers verified in vivo Biochem Moscow Suppl Ser B, 11 (1) (2017), pp. 43-54

36 B. Bao, A. Ahmad, A.S. Azmi, et al.Overview of cancer stem cells (CSCs) and mechanisms of their regulation: implications for cancer therapy Curr Protoc Pharmacol (2013;14 (14.25):1-18)

37 A. Mohan, R.R. Raj, G. Mohan, et al.Reporters of cancer stem cells as a tool for drug discovery Front Oncol, 11 (2021), Article 669250

38 C.A. Gilbert, A.H. RossCancer stem cells: cell culture, markers, and targets for new therapies J Cell Biochem, 108 (5) (2009), pp. 1031-1038

39 T. Yamashita, X.W. WangCancer stem cells in the development of liver cancer J Clin Invest, 123 (5) (2013), pp. 1911-1918

40 A.T. Collins, N.J. MaitlandProstate cancer stem cells Eur J Cancer, 42 (9) (2006), pp. 1213-1218

41 P. Huang, M. Watanabe, H. Kaku, et al.Cancer stem cell-like characteristics of a CD133+ subpopulation in the J82 human bladder cancer cell line Mol Clin Oncol, 1 (1) (2013), pp. 180-184

42 N. Hosen, C.Y. Park, N. Tatsumi, et al.CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia Proc Natl Acad Sci U S A, 104 (26) (2007), pp. 11008-11013

43 L. Jin, E.M. Lee, H.S. Ramshaw, et al.Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells Cell Stem Cell, 5 (1) (2009), pp. 31-42

44 T. Schatton, G.F. Murphy, N.Y. Frank, et al.Identification of cells initiating human melanomas Nature, 451 (7176) (2008), pp. 345-349

45 R.M. Zimmerer, P. Korn, P. Demougin, et al.Functional features of cancer stem cells in melanoma cell lines Cancer Cell Int, 13 (2013), p. 78

46 P.P. Szotek, R. Pieretti-Vanmarcke, P.T. Masiakos, et al.Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness Proc Natl Acad Sci U S A, 103 (30) (2006), pp. 11154-11159

47 I.A. Silva, S. Bai, K. McLean, et al.Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival Cancer Res, 71 (11) (2011), pp. 3991-4001

48 S. Liu, M.S. WichaTargeting breast cancer stem cells J Clin Oncol, 28 (25) (2010), pp. 4006-4012

49 M. Todaro, M.G. Francipane, J.P. Medema, et al.Colon cancer stem cells: promise of targeted therapy Gastroenterology, 138 (6) (2010), pp. 2151-2162

50 S. Takaishi, T. Okumura, S. Tu, et al.Identification of gastric cancer stem cells using the cell surface marker CD44 Stem Cell, 27 (5) (2009), pp. 1006-1020

51 Y. Jiang, Y. He, H. Li, et al.Expressions of putative cancer stem cell markers ABCB1, ABCG2, and CD133 are correlated with the degree of differentiation of gastric cancer Gastric Cancer, 15 (4) (2012), pp. 440-450

52 S. Krishnamurthy, J.E. NörHead and neck cancer stem cells J Dent Res, 91 (4) (2012), pp. 334-340

53 S. Gómez-López, R.G. Lerner, C. PetritschAsymmetric cell division of stem and progenitor cells during homeostasis and cancer Cell Mol Life Sci, 71 (4) (2014), pp. 575-597

54 Z. Huang, T. Wu, A.Y. Liu, et al.Differentiation and transdifferentiation potentials of cancer stem cells Oncotarget, 6 (37) (2015), pp. 39550-39563

55 N. Takebe, L. Miele, P.J. Harris, et al.Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update Nat Rev Clin Oncol, 12 (8) (2015), pp. 445-464

56 A. Torgovnick, B. SchumacherDNA repair mechanisms in cancer development and therapy Front Genet, 6 (2015), p. 157

57 J.C. ChangCancer stem cells: role in tumor growth, recurrence, metastasis, and treatment resistance Medicine, 95 (1 Suppl 1) (2016), pp. S20-S25

58 Y. Shiozawa, B. Nie, K.J. Pienta, et al.Cancer stem cells and their role in metastasis Pharmacol Ther, 138 (2) (2013), pp. 285-293

59 Y. Duchartre, Y.M. Kim, M. KahnThe Wnt signaling pathway in cancer Crit Rev Oncol Hematol, 99 (2016), pp. 141-149

60 J.K. Sethi, A. Vidal-PuigWnt signalling and the control of cellular metabolism Biochem J, 427 (1) (2010), pp. 1-17

61 S. Patel, A. Alam, R. Pant, et al.Wnt signaling and its significance within the tumor microenvironment: novel therapeutic insights Front Immunol, 10 (2019), p. 2872

62 K. Yang, X. Wang, H. Zhang, et al.The evolving roles of canonical WNT signaling in stem cells and tumorigenesis: implications in targeted cancer therapies Lab Invest, 96 (2) (2016), pp. 116-136

63 B.T. MacDonald, X. HeFrizzled and LRP5/6 receptors for Wnt/β-catenin signaling Cold Spring Harbor Perspect Biol, 4 (12) (2012), Article a007880

64 M. Katoh, M. KatohWNT signaling pathway and stem cell signaling network Clin Cancer Res, 13 (14) (2007), pp. 4042-4045

65 M. KatohCanonical and non-canonical WNT signaling in cancer stem cells and their niches: cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review) Int J Oncol, 51 (5) (2017), pp. 1357-1369

66 L. Qiao, B.C.Y. WongRole of Notch signaling in colorectal cancer Carcinogenesis, 30 (12) (2009), pp. 1979-1986

67 S. ChibaConcise review: Notch signaling in stem cell systems Stem Cell, 24 (11) (2006), pp. 2437-2447

68 C. Lobry, P. Oh, M.R. Mansour, et al.Notch signaling: switching an oncogene to a tumor suppressor Blood, 123 (16) (2014), pp. 2451-2459

69 P.W. Ingham, A.P. McMahonHedgehog signaling in animal development: paradigms and principles Genes Dev, 15 (23) (2001), pp. 3059-3087

70 L. Armas-López, J. Zúñiga, O. Arrieta, et al.The Hedgehog-GLI pathway in embryonic development and cancer: implications for pulmonary oncology therapy Oncotarget, 8 (36) (2017), pp. 60684-60703

71 L. Huminiecki, L. Goldovsky, S. Freilich, et al.Emergence, development and diversification of the TGF-beta signalling pathway within the animal kingdom BMC Evol Biol, 9 (2009), p. 28

72 Z. ZiMolecular engineering of the TGF-β signaling pathway J Mol Biol, 431 (15) (2019), pp. 2644-2654

73 F. Huang, Y.G. ChenRegulation of TGF-β receptor activity Cell Biosci, 2 (2012), p. 9

74 L.Y. Tang, M. Heller, Z. Meng, et al.Transforming growth factor-β (TGF-β) directly activates the JAK1-STAT3 axis to induce hepatic fibrosis in coordination with the SMAD pathway J Biol Chem, 292 (10) (2017), pp. 4302-4312

75 I. Ali, M.N. Lone, H.Y. Aboul-EneinImidazoles as potential anticancer agents Med Chem Commun, 8 (9) (2017), pp. 1742-1773

76 M. Michael, M.M. DohertyTumoral drug metabolism: overview and its implications for cancer therapy J Clin Oncol, 23 (2005), pp. 205-229

77 H. Shen, M.M. He, H. Liu, et al.Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17 Drug Metab Dispos, 35 (8) (2007), pp. 1292-1300

78 N. Rivlin, R. Brosh, M. Oren, et al.Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis Genes Cancer, 2 (4) (2011), pp. 466-474

79 T. Aas, A.L. Børresen, S. Geisler, et al.Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients Nat Med, 2 (7) (1996), pp. 811-814

80 M.S. Soengas, R.M. Alarcón, H. Yoshida, et al.Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition Science, 284 (5411) (1999), pp. 156-159

81 K. Cheung-Ong, G. Giaever, C. NislowDNA-damaging agents in cancer chemotherapy: serendipity and chemical biology Chem Biol, 20 (5) (2013), pp. 648-659

82 J. Zhou, Y. Kang, L. Chen, et al.The drug-resistance mechanisms of five platinum-based antitumor agents Front Pharmacol, 11 (2020), p. 343

83 C.H.A. Cheung, S.Y. Wu, T.R. Lee, et al.Cancer cells acquire mitotic drug resistance properties through beta I-tubulin mutations and alterations in the expression of beta-tubulin isotypes PLoS One, 5 (9) (2010), Article e12564

84 K. Mehta, J.Y. FokDrug Resistance in Cancer Cells Targeting transglutaminase-2 to overcome chemoresistance in cancer cells, Springer US, New York, NY (2009), pp. 95-114

85 D.J. Slamon, B. Leyland-Jones, S. Shak, et al.Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med, 344 (11) (2001), pp. 783-792

86 C. Holohan, S. Van Schaeybroeck, D.B. Longley, et al.Cancer drug resistance: an evolving paradigm Nat Rev Cancer, 13 (10) (2013), pp. 714-726

87 P. Koivisto, J. Kononen, C. Palmberg, et al.Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer Cancer Res, 57 (2) (1997), pp. 314-319

88 G. Chang, C.B. RothStructure of MsbA from E. coli: a homolog of the multidrug resistance ATP binding cassette (ABC) transporters Science, 293 (5536) (2001), pp. 1793-1800

89 Y. An, W.M. OngkekoABCG2:the key to chemoresistance in cancer stem cells? Expet Opin Drug Metabol Toxicol, 5 (12) (2009), pp. 1529-1542

90 T. Nakanishi, D.D. RossBreast cancer resistance protein (BCRP/ABCG2):its role in multidrug resistance and regulation of its gene expression Chin J Cancer, 31 (2) (2012), pp. 73-99

91 A.C. Jaramillo, F. Al Saig, J. Cloos, et al.How to overcome ATP-binding cassette drug efflux transporter-mediated drug resistance? Cancer Drug Resist, 1 (2018), pp. 6-29

92 L.Y. Li, Y.D. Guan, X.S. Chen, et al.DNA repair pathways in cancer therapy and resistance Front Pharmacol, 11 (2021), Article 629266

93 D. Huang, H. Duan, H. Huang, et al.Cisplatin resistance in gastric cancer cells is associated with HER2 upregulation-induced epithelial-mesenchymal transition Sci Rep, 6 (2016), Article 20502

94 A. ThorburnApoptosis and autophagy: regulatory connections between two supposedly different processes Apoptosis, 13 (1) (2008), pp. 1-9

95 N.A. Thomberry, Y. LaxebnikCaspases: enemies within Science, 281 (5381) (1998), pp. 1312-1316

96 E.A. Slee, C. Adrain, S.J. MartinSerial killers: ordering caspase activation events in apoptosis Cell Death Differ, 6 (11) (1999), pp. 1067-1074

97 I.F. SevrioukovaApoptosis-inducing factor: structure, function, and redox regulation Antioxidants Redox Signal, 14 (12) (2011), pp. 2545-2579

98 Y. Xia, S. Shen, I.M. VermaNF-κB, an active player in human cancers Cancer Immunol Res, 2 (9) (2014), pp. 823-830

99 M. Su, Y. Mei, S. SinhaRole of the crosstalk between autophagy and apoptosis in cancer JAMA Oncol, 2013 (2013), Article 102735

100 B. Jin, Y. Li, K.D. RobertsonDNA methylation: superior or subordinate in the epigenetic hierarchy? Genes Cancer, 2 (6) (2011), pp. 607-617

101 M. Witcher, B.M. EmersonEpigenetic silencing of the p16INK4a tumor suppressor is associated with loss of CTCF binding and a chromatin boundary Mol Cell, 34 (3) (2009), pp. 271-284

102 Y. Kondo, L.L. Shen, J.P.J. IssaCritical role of histone methylation in tumor suppressor gene silencing in colorectal cancer Mol Cell Biol, 23 (1) (2003), pp. 206-215

103 M. EhrlichDNA hypomethylation in cancer cells Epigenomics, 1 (2) (2009), pp. 239-259

104 M. Dratwa, B. Wysoczańska, P. Łacina, et al.TERT-regulation and roles in cancer formation Front Immunol, 11 (2020), Article 589929

105 L. Mariño-Ramírez, M.G. Kann, B.A. Shoemaker, et al.Histone structure and nucleosome stability Expert Rev Proteomics, 2 (5) (2005), pp. 719-729

106 J.E. Audia, R.M. CampbellHistone modifications and cancer Cold Spring Harbor Perspect Biol, 8 (4) (2016), Article a019521

107 V.K. Gangaraju, H. LinMicroRNAs: key regulators of stem cells Nat Rev Mol Cell Biol, 10 (2) (2009), pp. 116-125

108 A. Lujambio, S. Ropero, E. Ballestar, et al.Genetic unmasking of an epigenetically silenced microRNA in human cancer cells Cancer Res, 67 (4) (2007), pp. 1424-1429

109 E. Bandres, X. Agirre, N. Bitarte, et al.Epigenetic regulation of microRNA expression in colorectal cancer Int J Cancer, 125 (11) (2009), pp. 2737-2743

110 M. Marzagalli, F. Fontana, M. Raimondi, et al.Cancer stem cells-key players in tumor relapse Cancers, 13 (3) (2021), p. 376

111 S. Qin, J. Jiang, Y. Lu, et al.Emerging role of tumor cell plasticity in modifying therapeutic response Signal Transduct Targeted Ther, 5 (2020), p. 228

112 M. Quante, S.P. Tu, H. Tomita, et al.Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth Cancer Cell, 19 (2) (2011), pp. 257-272

113 G.L. SemenzaOxygen sensing, hypoxia-inducible factors, and disease pathophysiology Annu Rev Pathol, 9 (2014), pp. 47-71

114 G.L. SemenzaThe hypoxic tumor microenvironment: a driving force for breast cancer progression Biochim Biophys Acta, 1863 (3) (2016), pp. 382-391

115 S. Singh, C. Brocker, V. Koppaka, et al.Aldehyde dehydrogenases in cellular responses to oxidative/electrophilic stress Free Radic Biol Med, 56 (2013), pp. 89-101

116 C. Scheel, R.A. WeinbergPhenotypic plasticity and epithelial-mesenchymal transitions in cancer and normal stem cells? Int J Cancer, 129 (10) (2011), pp. 2310-2314

117 D.H. Kim, T. Xing, Z. Yang, et al.Epithelial mesenchymal transition in embryonic development, tissue repair and cancer: a comprehensive overview J Clin Med, 7 (1) (2018), p. 1

118 H. Wang, E. Chirshev, N. Hojo, et al.The epithelial-mesenchymal transcription factor SNAI1 represses transcription of the tumor suppressor miRNA let-7 in cancer Cancers, 13 (6) (2021), p. 1469

119 F. Sipos, O. GalambEpithelial-to-mesenchymal and mesenchymal-to-epithelial transitions in the colon World J Gastroenterol, 18 (7) (2012), pp. 601-608

120 E. Cruz da Silva, M. Dontenwill, L. Choulier, et al.Role of integrins in resistance to therapies targeting growth factor receptors in cancer Cancers, 11 (5) (2019), p. 692

121 R.C. Bates, A.M. MercurioThe epithelial-mesenchymal transition (EMT) and colorectal cancer progression Cancer Biol Ther, 4 (4) (2005), pp. 365-370

122 A.J. Galliher, W.P. SchiemannBeta3 integrin and Src facilitate transforming growth factor-beta mediated induction of epithelial-mesenchymal transition in mammary epithelial cells Breast Cancer Res, 8 (4) (2006), p. R42

123 T. Shibue, R.A. WeinbergIntegrin beta1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs Proc Natl Acad Sci U S A, 106 (25) (2009), pp. 10290-10295

124 A.S. Vadodkar, S. Suman, R. Lakshmanaswamy, et al.Chemoprevention of breast cancer by dietary compounds Anti Cancer Agents Med Chem, 12 (10) (2012), pp. 1185-1202

125 S. Sahebjam, L.L. Siu, A.A. RazakThe utility of hedgehog signaling pathway inhibition for cancer Oncol, 17 (8) (2012), pp. 1090-1099

126 A. AbidiHedgehog signaling pathway: a novel target for cancer therapy: vismodegib, a promising therapeutic option in treatment of basal cell carcinomas Indian J Pharmacol, 46 (1) (2014), pp. 3-12

127 Y. Yan, X. Zuo, D. WeiConcise review: emerging role of CD44 in cancer stem cells: a promising biomarker and therapeutic target Stem Cells Transl Med, 4 (9) (2015), pp. 1033-1043

128 M. Garofalo, C.M. CroceRole of microRNAs in maintaining cancer stem cells Adv Drug Deliv Rev, 81 (2015), pp. 53-61

129 F.T. Dao, L. Yang, Y.Z. Wang, et al.Characteristic and prognostic significance of leukemia stem cells associated antigens expressions in t (8;21) acute myeloid leukemia Zhonghua Xue Ye Xue Za Zhi, 40 (10) (2019), pp. 831-836

130 L. Luo, J. Zeng, B. Liang, et al.Ovarian cancer cells with the CD117 phenotype are highly tumorigenic and are related to chemotherapy outcome Exp Mol Pathol, 91 (2) (2011), pp. 596-602

131 L. Zhao, Y. Yang, P. Zhou, et al.Targeting CD133high colorectal cancer cells in vitro and in vivo with an asymmetric bispecific antibody J Immunother, 38 (6) (2015), pp. 217-228

132 H. Long, T. Xiang, W. Qi, et al.CD133+ ovarian cancer stem-like cells promote non-stem cancer cell metastasis via CCL5 induced epithelial-mesenchymal transition Oncotarget, 6 (8) (2015), pp. 5846-5859

133 P.R. Ding, A.K. Tiwari, S. Ohnuma, et al.The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein transporter PLoS One, 6 (4) (2011), Article e19329

134 G. Navarro, R.R. Sawant, S. Biswas, et al.P-glycoprotein silencing with siRNA delivered by DOPE-modified PEI overcomes doxorubicin resistance in breast cancer cells Nanomedicine, 7 (1) (2012), pp. 65-78

135 T.E. Lans, D.J. Grünhagen, J.H.W. de Wilt, et al.Isolated limb perfusions with tumor necrosis factor and melphalan for locally recurrent soft tissue sarcoma in previously irradiated limbs Ann Surg Oncol, 12 (5) (2005), pp. 406-411

136 J.P. Higgins, M.B. Bernstein, J.W. HodgeEnhancing immune responses to tumor-associated antigens Cancer Biol Ther, 8 (15) (2009), pp. 1440-1449

137 Y. Guo, K. Feng, Y. Wang, et al.Targeting cancer stem cells by using chimeric antigen receptor-modified T cells: a potential and curable approach for cancer treatment Protein Cell, 9 (6) (2018), pp. 516-526

138 K. Wang, G. Wei, D. LiuCD19:a biomarker for B cell development, lymphoma diagnosis and therapy Exp Hematol Oncol, 1 (2012), p. 36

139 M. EngelhardAnti-CD20 antibody treatment of non-Hodgkin lymphomas Clin Immunol, 172 (2016), pp. 101-104

140 H. Stein, H.D. Foss, H. Dürkop, et al.CD30+ anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features Blood, 96 (12) (2000), pp. 3681-3695

141 R.B. Walter, F.R. Appelbaum, E.H. Estey, et al.Acute myeloid leukemia stem cells and CD33-targeted immunotherapy Blood, 119 (26) (2012), pp. 6198-6208

142 F.J. Vojdeman, S.E.M. Herman, N. Kirkby, et al.Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia Leuk Lymphoma, 58 (10) (2017), pp. 2356-2362

143 E. Agostinetto, F. Montemurro, F. Puglisi, et al.Immunotherapy for HER2-positive breast cancer: clinical evidence and future perspectives Cancers, 14 (9) (2022), p. 2136

144 K.K.W. To, W. Fong, W.C.S. ChoImmunotherapy in treating EGFR-mutant lung cancer: current challenges and new strategies Front Oncol, 11 (2021), Article 635007

145 T.F. Hansen, C. Qvortrup, P. PfeifferAngiogenesis inhibitors for colorectal cancer. a review of the clinical data Cancers, 13 (5) (2021), p. 1031

146 Kankanala V.L., Mukkamalla S.K.R.Carcinoembryonic Antigen. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022.

147 M.Y. Liao, J.K. Lai, M.Y.P. Kuo, et al.An anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer Oncotarget, 6 (28) (2015), pp. 24947-24968

148 J. Wang, W. Hu, K. Wang, et al.Repertaxin, an inhibitor of the chemokine receptors CXCR1 and CXCR2, inhibits malignant behavior of human gastric cancer MKN45 cells in vitro and in vivo and enhances efficacy of 5-fluorouracil Int J Oncol, 48 (4) (2016), pp. 1341-1352

149 C. Ginestier, E. Charafe-Jauffret, D. BirnbaumTargeting breast cancer stem cells: fishing season open Breast Cancer Res, 12 (5) (2010), p. 312

150 S.K. Burroughs, S. Kaluz, D. Wang, et al.Hypoxia inducible factor pathway inhibitors as anticancer therapeutics Future Med Chem, 5 (5) (2013), pp. 553-572

151 L. Horn, A.B. SandlerEmerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer Clin Lung Cancer, 10 (Suppl 1) (2009), pp. S7-S16

152 S. Senapati, A.K. Mahanta, S. Kumar, et al.Controlled drug delivery vehicles for cancer treatment and their performance Signal Transduct Targeted Ther, 3 (2018), p. 7

153 Y. Zhou, J. Yang, J. KopečekSelective inhibitory effect of HPMA copolymer-cyclopamine conjugate on prostate cancer stem cells Biomaterials, 33 (6) (2012), pp. 1863-1872

154 X. Wei, T.H. Senanayake, G. Warren, et al.Hyaluronic acid-based nanogel-drug conjugates with enhanced anticancer activity designed for the targeting of CD44-positive and drug-resistant tumors Bioconjugate Chem, 24 (4) (2013), pp. 658-668

155 Y. Tang, Y. Chen, Z. Zhang, et al.Nanoparticle-based RNAi therapeutics targeting cancer stem cells: update and prospective Pharmaceutics, 13 (12) (2021), p. 2116

156 A.S. Correia, F. Gärtner, N. ValeDrug combination and repurposing for cancer therapy: the example of breast cancer Heliyon, 7 (1) (2021), Article e05948

157 R. Bayat Mokhtari, T.S. Homayouni, N. Baluch, et al.Combination therapy in combating cancer Oncotarget, 8 (23) (2017), pp. 38022-38043

158 J. Huang, C. Tao, Y. Yu, et al.Simultaneous targeting of differentiated breast cancer cells and breast cancer stem cells by combination of docetaxel- and sulforaphane-loaded self-assembled poly(D, L-lactide-co-glycolide)/hyaluronic acid block copolymer-based nanoparticles J Biomed Nanotechnol, 12 (7) (2016), pp. 1463-1477

159 B. Feinberg, J. Kish, I. Dokubo, et al.Reports of the demise of chemotherapy have been greatly exaggerated Am J Manag Care, 25 (6) (2019), pp. 270-272

160 S.M. Paul, D.S. Mytelka, C.T. Dunwiddie, et al.How to improve R&D productivity: the pharmaceutical industry's grand challenge Nat Rev Drug Discov, 9 (3) (2010), pp. 203-214

161 S. Hoelder, P.A. Clarke, P. WorkmanDiscovery of small molecule cancer drugs: successes, challenges and opportunities Mol Oncol, 6 (2) (2012), pp. 155-176

162 M. Siddiqui, S.V. RajkumarThe high cost of cancer drugs and what we can do about it Mayo Clin Proc, 87 (10) (2012), pp. 935-943

163 J.A. DiMasi, R.W. Hansen, H.G. GrabowskiThe price of innovation: new estimates of drug development costs J Health Econ, 22 (2) (2003), pp. 151-185

164 Y. Cha, T. Erez, I.J. Reynolds, et al.Drug repurposing from the perspective of pharmaceutical companies Br J Pharmacol, 175 (2) (2018), pp. 168-180

165 S. Aggarwal, S.S. Verma, S. Aggarwal, et al.Drug repurposing for breast cancer therapy: old weapon for new battle Semin Cancer Biol, 68 (2021), pp. 8-20

166 C.A. Umscheid, D.J. Margolis, C.E. GrossmanKey concepts of clinical trials: a narrative review Postgrad Med, 123 (5) (2011), pp. 194-204

167 M. OmejcDrug development: the journey of a medicine from lab to shelf J Dev Drugs, 9 (1) (2020), p. e115

168 A. AkhtarThe flaws and human harms of animal experimentation Camb Q Healthc Ethics, 24 (4) (2015), pp. 407-419

169 E. Chilet-RosellGender bias in clinical research, pharmaceutical marketing, and the prescription of drugs Glob Health Action, 7 (2014), Article 25484

170 A. Undas, K.E. Brummel-Ziedins, K.G. MannAntithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions Blood, 109 (6) (2007), pp. 2285-2292

171 X.H. Liu, A. Kirschenbaum, S. Yao, et al.Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo J Urol, 164 (3) (2000), pp. 820-825

172 P. Gautret, J.C. Lagier, P. Parola, et al.Hydroxychloroquine and azithromycin as a treatment of COVID-19:results of an open label non-randomized clinical trial Int J Antimicrob Agents, 56 (1) (2020), Article 105949

173 J.R. Hughes, L.F. Stead, J. Hartmann-Boyce, et al.Antidepressants for smoking cessation Cochrane Database Syst Rev, 2014 (1) (2014), p. CD000031

174 Y. Acharya, A. SayedChloroquine and hydroxychloroquine as a repurposed agent against COVID-19: a narrative review Ther Adv Infect Dis, 7 (2020), Article 2049936120947517

175 M. Plaze, D. Attali, A.C. Petit, et al.Repurposing chlorpromazine to treat COVID-19: the recovery study L’Encéphale, 46 (3) (2020), pp. 169-172

176 L. Chiu, C.H. Lo, M. Shen, et al.Colchicine use in patients with COVID-19: a systematic review and meta-analysis PLoS One, 16 (12) (2021), Article e0261358

177 C.H. ScheinRepurposing approved drugs for cancer therapy Br Med Bull, 137 (1) (2021), pp. 13-27

178 S.D. Thomas, N.K. Jha, B. Sadek, et al.Repurposing dimethyl fumarate for cardiovascular diseases: pharmacological effects, molecular mechanisms, and therapeutic promise Pharmaceuticals, 15 (5) (2022), p. 497

179 M. Steiner, S. Steinberg, D. Stewart, et al.Fluoxetine in the treatment of premenstrual Dysphoria. Canadian fluoxetine/premenstrual Dysphoria collaborative study group N Engl J Med, 332 (23) (1995), pp. 1529-1534

180 P. Suchonwanit, S. Thammarucha, K. LeerunyakulMinoxidil and its use in hair disorders: a review Drug Des Dev Ther, 13 (2019), pp. 2777-2786

181 J.H. Beigel, K.M. Tomashek, L.E. Dodd, et al.Remdesivir for the treatment of Covid-19 - final report N Engl J Med, 383 (19) (2020), pp. 1813-1826

182 M. Rudrapal, S.J. Khairnar, A.G. JadhavDrug repurposing (DR): an emerging approach in drug discovery F.A. Badria (Ed.), Drug Repurposing - Hypothesis, Molecular Aspects and Therapeutic Applications [Internet], IntechOpen, London (2020)

183 S. Burock, S. Daum, U. Keilholz, et al.Phase II trial to investigate the safety and efficacy of orally applied niclosamide in patients with metachronous or sychronous metastases of a colorectal cancer progressing after therapy: the NIKOLO trial BMC Cancer, 18(1) (2018), p. 297

184 C.T. Yeh, A.T.H. Wu, P.M.H. Chang, et al.Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug resistance of lung cancer Am J Respir Crit Care Med, 186 (11) (2012), pp. 1180-1188

185 W.S. Heng, S.C. CheahChelerythrine chloride downregulates β-catenin and inhibits stem cell properties of non-small cell lung carcinoma Molecules, 25 (1) (2020), p. 224

186 P.B. Gupta, T.T. Onder, G. Jiang, et al.Identification of selective inhibitors of cancer stem cells by high-throughput screening Cell, 138 (4) (2009), pp. 645-659

187 M. Shaimerdenova, O. Karapina, D. Mektepbayeva, et al.The effects of antiviral treatment on breast cancer cell line Infect Agent Cancer, 12 (2017), p. 18

188 Y.C. Lim, H.J. Kang, Y.S. Kim, et al.All-trans-retinoic acid inhibits growth of head and neck cancer stem cells by suppression of Wnt/β-catenin pathway Eur J Cancer, 48 (17) (2012), pp. 3310-3318

189 M.S. Kim, B.C. Yoo, W.S. Yang, et al.Src is the primary target of aripiprazole, an atypical antipsychotic drug, in its anti-tumor action Oncotarget, 9 (5) (2017), pp. 5979-5992

190 Y. Augustin, H.M. Staines, S. KrishnaArtemisinins as a novel anti-cancer therapy: targeting a global cancer pandemic through drug repurposing Pharmacol Ther, 216 (2020), Article 107706

191 B. Qorri, W. Harless, M.R. SzewczukNovel molecular mechanism of aspirin and celecoxib targeting mammalian neuraminidase-1 impedes epidermal growth factor receptor signaling axis and induces apoptosis in pancreatic cancer cells Drug Des Dev Ther, 14 (2020), pp. 4149-4167

192 M. Jin, C. Li, Q. Zhang, et al.Effects of aspirin on proliferation, invasion and apoptosis of Hep-2 cells via the PTEN/AKT/NF-κB/survivin signaling pathway Oncol Lett, 15 (6) (2018), pp. 8454-8460

193 S. Suzuki, M. Yamamoto, K. Togashi, et al.In vitro and in vivo anti-tumor effects of brexpiprazole, a newly-developed serotonin-dopamine activity modulator with an improved safety profile Oncotarget, 10 (37) (2019), pp. 3547-3558

194 S. Zeng, M. Pöttler, B. Lan, et al.Chemoresistance in pancreatic cancer Int J Mol Sci, 20 (18) (2019), p. 4504

195 P. Pantziarka, G. Bouche, L. Meheus, et al.Repurposing drugs in oncology (ReDO)-cimetidine as an anti-cancer agent Ecancermedicalscience, 8 (2014), p. 485

196 C. Pfab, L. Schnobrich, S. Eldnasoury, et al.Repurposing of antimicrobial agents for cancer therapy: what do we know? Cancers, 13 (13) (2021), p. 3193

197 D.S. Choi, E. Blanco, Y.S. Kim, et al.Chloroquine eliminates cancer stem cells through deregulation of Jak2 and DNMT1 Stem Cell, 32 (9) (2014), pp. 2309-2323

198 P.P. Sordillo, L. HelsonCurcumin and cancer stem cells: curcumin has asymmetrical effects on cancer and normal stem cells Anticancer Res, 35 (2) (2015), pp. 599-614

199 J.Y. Tang, P.L. So, E.H. Epstein Jr.Novel Hedgehog pathway targets against basal cell carcinoma Toxicol Appl Pharmacol, 224 (3) (2007), pp. 257-264

200 P. Pantziarka, V. Sukhatme, G. Bouche, et al.Repurposing drugs in oncology (ReDO)-diclofenac as an anti-cancer agent Ecancermedicalscience, 10 (2016), p. 610

201 D. Han, G. Wu, C. Chang, et al.Disulfiram inhibits TGF-β-induced epithelial-mesenchymal transition and stem-like features in breast cancer via ERK/NF-κB/Snail pathway Oncotarget, 6 (38) (2015), pp. 40907-40919

202 L. Zhang, L. Xu, F. Zhang, et al.Doxycycline inhibits the cancer stem cell phenotype and epithelial-to-mesenchymal transition in breast cancer Cell Cycle, 16 (8) (2017), pp. 737-745

203 S. Toden, H.M. Tran, O.A. Tovar-Camargo, et al.Epigallocatechin-3-gallate targets cancer stem-like cells and enhances 5-fluorouracil chemosensitivity in colorectal cancer Oncotarget, 7 (13) (2016), pp. 16158-16171

204 L. Zhang, L. Li, M. Jiao, et al.Genistein inhibits the stemness properties of prostate cancer cells through targeting Hedgehog-Gli1 pathway Cancer Lett, 323 (1) (2012), pp. 48-57

205 T.T. Mai, J. Moon, Y. Song, et al.Ginsenoside F2 induces apoptosis accompanied by protective autophagy in breast cancer stem cells Cancer Lett, 321 (2) (2012), pp. 144-153

206 M.J. Ruiz-Magaña, R. Martínez-Aguilar, E. Lucendo, et al.The antihypertensive drug hydralazine activates the intrinsic pathway of apoptosis and causes DNA damage in leukemic T cells Oncotarget, 7 (16) (2016), pp. 21875-21886

207 S. Amatori, I. Bagaloni, B. Donati, et al.DNA demethylating antineoplastic strategies: a comparative point of view Genes Cancer, 1 (3) (2010), pp. 197-209

208 H. Akrami, B. Moradi, D. Borzabadi Farahani, et al.Ibuprofen reduces cell proliferation through inhibiting Wnt/β catenin signaling pathway in gastric cancer stem cells Cell Biol Int, 42 (8) (2018), pp. 949-958

209 C.M. Moon, J.H. Kwon, J.S. Kim, et al.Nonsteroidal anti-inflammatory drugs suppress cancer stem cells via inhibiting PTGS2 (cyclooxygenase 2) and NOTCH/HES1 and activating PPARG in colorectal cancer Int J Cancer, 134 (3) (2014), pp. 519-529

210 H. Tsubamoto, T. Ueda, K. Inoue, et al.Repurposing itraconazole as an anticancer agent Oncol Lett, 14 (2) (2017), pp. 1240-1246

211 A.E. Guerini, L. Triggiani, M. Maddalo, et al.Mebendazole as a candidate for drug repurposing in oncology: an extensive review of current literature Cancers, 11 (9) (2019), p. 1284

212 C. Stolfi, F. Pallone, G. MonteleoneColorectal cancer chemoprevention by mesalazine and its derivatives J Biomed Biotechnol, 2012 (2012), Article 980458

213 H.A. Hirsch, D. Iliopoulos, P.N. Tsichlis, et al.Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission Cancer Res, 69 (19) (2009), pp. 7507-7511

214 T. Saito, T. Chiba, K. Yuki, et al.Metformin, a diabetes drug, eliminates tumor-initiating hepatocellular carcinoma cells PLoS One, 8 (7) (2013), Article e70010

215 B. Zhao, J. Luo, Y. Wang, et al.Metformin suppresses self-renewal ability and tumorigenicity of osteosarcoma stem cells via reactive oxygen species-mediated apoptosis and autophagy Oxid Med Cell Longev, 2019 (2019), Article 9290728

216 C. Blanquicett, J. Roman, C.M. HartThiazolidinediones as anti-cancer agents Cancer Ther, 6 (A) (2008), pp. 25-34

217 Y. Li, P.K. Li, M.J. Roberts, et al.Multi-targeted therapy of cancer by niclosamide: a new application for an old drug Cancer Lett, 349 (1) (2014), pp. 8-14

218 M. Boesch, A.G. Zeimet, H. Rumpold, et al.Drug transporter-mediated protection of cancer stem cells from ionophore antibiotics Stem Cells Transl Med, 4 (9) (2015), pp. 1028-1032

219 P. Yuan, K. Ito, R. Perez-Lorenzo, et al.Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma Proc Natl Acad Sci U S A, 110 (45) (2013), pp. 18226-18231

220 M. Kakarala, D.E. Brenner, H. Korkaya, et al.Targeting breast stem cells with the cancer preventive compounds curcumin and piperine Breast Cancer Res Treat, 122 (3) (2010), pp. 777-785

221 L. Zhang, H.J. Yao, Y. Yu, et al.Mitochondrial targeting liposomes incorporating daunorubicin and quinacrine for treatment of relapsed breast cancer arising from cancer stem cells Biomaterials, 33 (2) (2012), pp. 565-582

222 V.G. VogelUpdate on raloxifene: role in reducing the risk of invasive breast cancer in postmenopausal women Breast Cancer (Dove Med Press), 3 (2011), pp. 127-137

223 T. Takahara, Y. Amemiya, R. Sugiyama, et al.Amino acid-dependent control of mTORC1 signaling: a variety of regulatory modes J Biomed Sci, 27 (2020), p. 87

224 Z. Zhang, L. Zhou, N. Xie, et al.Overcoming cancer therapeutic bottleneck by drug repurposing Signal Transduct Targeted Ther, 5 (2020), p. 113

225 L. Elisa, C.A. Leslie, W. Christina, et al.Targeting cancer stem cell survival in plasma cell leukemia with a pan-BCL2 inhibitor Blood, 126 (23) (2015), p. 5351

226 Y. Lu, W. Ma, J. Mao, et al.Salinomycin exerts anticancer effects on human breast carcinoma MCF-7 cancer stem cells via modulation of Hedgehog signaling Chem Biol Interact, 228 (2015), pp. 100-107

227 C. Dai, P. Liu, X. Wang, et al.The antipsychotic agent sertindole exhibited antiproliferative activities by inhibiting the STAT3 signaling pathway in human gastric cancer cells J Cancer, 11 (4) (2020), pp. 849-857

228 S. Ohba, Y. Hirose, T. Kawase, et al.Inhibition of c-Jun N-terminal kinase enhances temozolomide-induced cytotoxicity in human glioma cells J Neuro Oncol, 95 (3) (2009), pp. 307-316

229 M.T. Montales, O.M. Rahal, J. Kang, et al.Repression of mammosphere formation of human breast cancer cells by soy isoflavone genistein and blueberry polyphenolic acids suggests diet-mediated targeting of cancer stem-like/progenitor cells Carcinogenesis, 33 (3) (2012), pp. 652-660

230 X. Wang, Y. Li, Y. Dai, et al.Sulforaphane improves chemotherapy efficacy by targeting cancer stem cell-like properties via the miR-124/IL-6R/STAT3 axis Sci Rep, 6 (2016), Article 36796

231 H.W. Cheng, Y.H. Liang, Y.L. Kuo, et al.Identification of thioridazine, an antipsychotic drug, as an antiglioblastoma and anticancer stem cell agent using public gene expression data Cell Death Dis, 6 (5) (2015), Article e1753

232 C. Pérez-Plasencia, T. Padilla-Benavides, E. López-Urrutia, et al.Editorial: repurposed drugs targeting cancer signaling pathways: clinical insights to improve oncologic therapies Front Oncol, 11 (2021), Article 713040

233 Drug Repurposing Anticancerfund.org. (2022) https://www.anticancerfund.org/en/projects?f%5B0%5D=field_focus_area_ref%3A21

234 A. Hosseini, A. GhorbaniCancer therapy with phytochemicals: evidence from clinical studies Avicenna J Phytomed, 5 (2) (2015), pp. 84-97

235 M.A. Rahman, M.A. Hannan, R. Dash, et al.Phytochemicals as a complement to cancer chemotherapy: pharmacological modulation of the autophagy-apoptosis pathway Front Pharmacol, 12 (2021), Article 639628

236 A. Ranjan, S. Ramachandran, N. Gupta, et al.Role of phytochemicals in cancer prevention Int J Mol Sci, 20 (20) (2019), p. 4981

237 H. Ishikawa, T. Saeki, T. Otani, et al.Aged garlic extract prevents a decline of NK cell number and activity in patients with advanced cancer J Nutr, 136 (3 Suppl) (2006), pp. 816S-820S

238 H. Wang, Y. Wang, H. Gao, et al.Piperlongumine induces apoptosis and autophagy in leukemic cells through targeting the PI3K/Akt/mTOR and p38 signaling pathways Oncol Lett, 15 (2) (2018), pp. 1423-1428

239 K.C. Pramanik, N.M. Fofaria, P. Gupta, et al.Inhibition of β-catenin signaling suppresses pancreatic tumor growth by disrupting nuclear β-catenin/TCF-1 complex: critical role of STAT-3 Oncotarget, 6 (13) (2015), pp. 11561-11574

240 T.L. Adetunji, F. Olawale, C. Olisah, et al.Capsaicin: a two-decade systematic review of global research output and recent advances against human cancer Front Oncol, 12 (2022), Article 908487

241 T.A. Zughaibi, M. Suhail, M. Tarique, et al.Targeting PI3K/Akt/mTOR pathway by different flavonoids: a cancer chemopreventive approach Int J Mol Sci, 22 (22) (2021), Article 12455

242 S.W. Hung, Y. Li, X. Chen, et al.Green tea epigallocatechin-3-gallate regulates autophagy in male and female reproductive cancer Front Pharmacol, 13 (2022), Article 906746

243 M.N. Motiwala, V.D. RangariCombined effect of paclitaxel and piperine on a MCF-7 breast cancer cell line in vitro: evidence of a synergistic interaction Synergy, 2 (1) (2015), pp. 1-6

244 S. Pushpa Ragini, A.V. Naga Divya, Ch Anusha, et al.Enhancement of paclitaxel and doxorubicin cytotoxicity in breast cancer cell lines in combination with piperine treatment and analysis of expression of autophagy and apoptosis genes J Med Sci Res, 2 (2) (2014), pp. 62-67

245 C. Bose, S. Awasthi, R. Sharma, et al.Sulforaphane potentiates anticancer effects of doxorubicin and attenuates its cardiotoxicity in a breast cancer model PLoS One, 13 (3) (2018), Article e0193918

246 Ç. Şakalar, K. İzgi, B. İskender, et al.The combination of thymoquinone and paclitaxel shows anti-tumor activity through the interplay with apoptosis network in triple-negative breast cancer Tumor Biol, 37 (4) (2016), pp. 4467-4477

247 H.A. Bashmail, A.A. Alamoudi, A. Noorwali, et al.Thymoquinone synergizes gemcitabine anti-breast cancer activity via modulating its apoptotic and autophagic activities Sci Rep, 8 (2018), Article 11674

248 A.A. Dayem, H.Y. Choi, J.H. Kim, et al.Role of oxidative stress in stem, cancer, and cancer stem cells Cancers, 2 (2) (2010), pp. 859-884

249 H.R. Sun, S. Wang, S.C. Yan, et al.Therapeutic strategies targeting cancer stem cells and their microenvironment Front Oncol, 9 (2019), p. 1104

250 R.C. Yuen, S.Y. TsaoEmbracing cancer immunotherapy with vital micronutrients World J Clin Oncol, 12 (9) (2021), pp. 712-724

251 R.E. KastPotential for all-trans retinoic acid (tretinoin) to enhance interferon-alpha treatment response in chronic myelogenous leukemia, melanoma, myeloma and renal cell carcinoma Cancer Biol Ther, 7 (10) (2008), pp. 1515-1519

252 O.D. Martino, J.S. WelchRetinoic acid receptors in acute myeloid leukemia therapy Cancers, 11 (12) (2019), p. 1915

253 R.Z. Stolzenberg-Solomon, D. Albanes, F.J. Nieto, et al.Pancreatic cancer risk and nutrition-related methyl-group availability indicators in male smokers J Natl Cancer Inst, 91 (6) (1999), pp. 535-541

254 R. Kaaks, A.J. Tuyns, M. Haelterman, et al.Nutrient intake patterns and gastric cancer risk: a case-control study in Belgium Int J Cancer, 78 (4) (1998), pp. 415-420

255 E. Negri, S. Franceschi, C. Bosetti, et al.Selected micronutrients and oral and pharyngeal cancer Int J Cancer, 86 (2000), pp. 122-127

256 T.J. Hartman, K. Woodson, R. Stolzenberg-Solomon, et al.Association of the B-vitamins pyridoxal 5'-phosphate (B6), B12, and folate with lung cancer risk in older men Am J Epidemiol, 153 (7) (2001), pp. 688-694

257 T.J. Key, P.B. Silcocks, G.K. Davey, et al.A case-control study of diet and prostate cancer Br J Cancer, 76 (5) (1997), pp. 678-687

258 C. Ginestier, J. Wicinski, N. Cervera, et al.Retinoid signaling regulates breast cancer stem cell differentiation Cell Cycle, 8 (20) (2009), pp. 3297-3302

259 V. De Laurenzi, G. Melino, I. Savini, et al.Cell death by oxidative stress and ascorbic acid regeneration in human neuroectodermal cell lines Eur J Cancer, 31 (4) (1995), pp. 463-466

260 E.M. De Francesco, G. Bonuccelli, M. Maggiolini, et al.Vitamin C and Doxycycline: a synthetic lethal combination therapy targeting metabolic flexibility in cancer stem cells (CSCs) Oncotarget, 8 (40) (2017), pp. 67269-67286

261 J.Y. So, N. SuhTargeting cancer stem cells in solid tumors by vitamin D J Steroid Biochem Mol Biol, 148 (2015), pp. 79-85